Medical Device Start-Up News, August 2012

This month we profile CoolSpine and its catheter-based hypothermia device, Inseal Medical and its large-bore vascular closure device, and MitrAssist Medical, which is developing a valve-in-valve approach to treating mitral regurgitation.

In many cardiology applications, companies developing vascular closure devices face an uphill battle. Vascular closure devices aid in sealing the puncture that’s made in the femoral artery to enable access to the vasculature. They’re adjunctive technologies that add costs to procedures, while competing with manual compression (pushing down on the wound by hand), a low cost, low-tech standard of care. In routine angioplasties and stent implantation procedures it is a matter of physician preference whether to use a closure device or to simply rely on compression. However, now that the femoral artery is being used to advance transcatheter aortic valves and other large devices for the treatment of structural heart disease, the demand for new tools for access site management changes from “nice-to-have” to “need-to-have.” (See Also see "As TAVI Advances, Adjunctive Devices Multiply" - Medtech Insight, 16 December, 2011..)

Avi Penner, PhD, founded Inseal Medical Ltd. in 2008 to develop a closure device designed to fill this new need. Penner explains that with respect to vascular access and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.